NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.

医学 胆道癌 顺铂 胆道 癌症 肿瘤科 内科学 化疗 吉西他滨
作者
Jennifer J. Knox,Mairéad G McNamara,Daniel H. Palmer,T.R.J. Evans,David Goldstein,John Bridgewater,Juan W. Valle
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
被引量:3
标识
DOI:10.1200/jco.2019.37.15_suppl.tps4156
摘要

TPS4156 Background: Cisplatin and gemcitabine (CisGem) is the global standard of care for 1 st -line treatment of patients (pts) with advanced biliary tract cancer (BTC). No agents have regulatory approval for this disease. CisGem achieves an objective response rate (ORR) of 26% and median overall survival (OS) of 11.7 months (ABC-02). Key cancer resistance mechanisms limit gemcitabine efficacy. NUC-1031, a phosphoramidate transformation of gemcitabine, is designed to overcome resistance mechanisms associated with poor gemcitabine response. Promising signs of efficacy have been observed with single agent in a phase I study in solid tumors (Blagden et al 2018) and in the phase Ib ABC-08 study of NUC-1031 + cisplatin 25 mg /m 2 d1, d8 q 21 days for the 1 st -line treatment of advanced BTC. 14 pts have been enrolled across 2 cohorts (NUC-1031: 625 mg/m 2 and 725 mg/m 2 ). In 11 pts evaluable for response ORR was 64% (1 CR, 6 PRs) and DCR was 73%. PFS/OS data is maturing. The combination was very well-tolerated with no unexpected adverse events or dose-limiting toxicities. The RP2D in combination with cisplatin is 725 mg/ m 2 . Safety, coupled with encouraging efficacy signal has led to initiation of a global Phase III development program. Methods: A Phase III, open-label, randomized head-to-head study of NUC-1031 + cisplatin versus CisGem for the 1 st -line treatment of advanced BTC will include pts ≥18 years with histologically- or cytologically-proven BTC (including cholangiocarcinoma, gallbladder, or ampullary cancer), that is not resectable and who have had no prior systemic chemotherapy for locally advanced/metastatic disease. A total of 828 pts will be randomized (1:1) to either 725 mg/m 2 NUC-1031 + 25 mg/m 2 cisplatin or 1000 mg/m 2 gemcitabine + 25 mg/m 2 cisplatin, administered on Days 1 and 8 of a 21-day cycle, respectively. Primary objectives are OS and ORR. Secondary objectives include further measurements of efficacy, safety, pharmacokinetics, and patient-reported quality of life. The study will be conducted at approximately 120 sites across North America, Europe and Asia Pacific countries. Clinical trial information: NCT02351765.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
qiancib202完成签到,获得积分0
6秒前
6秒前
ice发布了新的文献求助10
9秒前
迅速的念芹完成签到 ,获得积分10
10秒前
12秒前
Dogged完成签到 ,获得积分10
14秒前
cfw完成签到,获得积分10
14秒前
大意的火龙果完成签到 ,获得积分10
14秒前
Harold完成签到,获得积分10
18秒前
cfw发布了新的文献求助10
18秒前
幸运小张完成签到,获得积分0
19秒前
乐观寻芹完成签到,获得积分10
23秒前
从容的水壶完成签到 ,获得积分10
24秒前
彩色人生完成签到 ,获得积分10
26秒前
27秒前
daikai完成签到 ,获得积分10
27秒前
宗剑完成签到,获得积分10
30秒前
心无杂念完成签到 ,获得积分10
31秒前
LJ_2完成签到 ,获得积分0
38秒前
高贵觅山完成签到,获得积分10
38秒前
keyan完成签到,获得积分10
40秒前
Shulug完成签到 ,获得积分10
40秒前
李可以完成签到 ,获得积分10
42秒前
weven完成签到 ,获得积分10
46秒前
foyefeng完成签到,获得积分10
48秒前
lllll完成签到 ,获得积分10
1分钟前
lzr完成签到 ,获得积分10
1分钟前
友好的晓曼完成签到,获得积分10
1分钟前
白鱼neko完成签到 ,获得积分10
1分钟前
木卫二完成签到 ,获得积分10
1分钟前
xiaoxiao完成签到 ,获得积分10
1分钟前
momo完成签到 ,获得积分10
1分钟前
风格完成签到,获得积分10
1分钟前
1分钟前
水煮电吹风的应助被雪山飞龙采纳,获得10
1分钟前
醉酒当歌完成签到 ,获得积分10
1分钟前
侯子完成签到 ,获得积分10
1分钟前
追寻微笑完成签到 ,获得积分10
1分钟前
勤劳的唇膏完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180053
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808682
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012